Skip to main content
ELI LILLY & Co logo

ELI LILLY & Co — Investor Relations & Filings

Ticker · LLY ISIN · US5324571083 LEI · FRDRIPF3EKNDJ2CQJL29 US Manufacturing
Open in API
Filings indexed 3,870 across all filing types
Latest filing 2019-02-07 Director's Dealing
Country US United States of America
Listing US LLY

About ELI LILLY & Co

https://www.lilly.com/

Eli Lilly and Company is a global, research-based medicine company that discovers, develops, manufactures, and sells pharmaceutical products. The company focuses on creating treatments in key therapeutic areas, including diabetes, obesity, immunology, oncology, and neuroscience. Leveraging biotechnology and chemistry, it develops medicines for some of the world's most significant health challenges. Historically known for the commercialization of insulin, the company continues to be a major provider of therapies for chronic diseases. Its stated purpose is to unite caring with discovery to create medicines that make life better for people around the world.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2019-02-07 English
FORM 4
Director's Dealing
2019-02-07 English
FORM 4
Director's Dealing
2019-02-07 English
FORM 4
Director's Dealing
2019-02-07 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is filed pursuant to Rule 425 under the Securities Act of 1933, which relates to communications in connection with a securities offering, specifically an exchange offer. The text includes excerpts from a webcast discussing the planned separation of Elanco Animal Health from Eli Lilly and Company, focusing on the exchange offer and related transitional service agreements. It contains forward-looking statements and disclaimers typical of securities offering communications. There is no detailed financial data, no full report, and no certification. The document is an announcement and communication related to a merger or acquisition event, specifically the exchange offer as part of a separation transaction. Given the context and the Rule 425 filing nature, this document fits best under the category of Merger & Acquisition (MA) filings, which include merger communications and tender offer documents. The document length is sufficient and the content is substantive about the transaction but not a full report or proxy statement. Therefore, the classification is MA with high confidence.
2019-02-07 English
FORM 4/A
Director's Dealing
2019-02-06 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.